Evidence map›Paper›PMID 19339244›Full record

ArticleThe Journal of biological chemistry2009

FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor beta-mediated regulation of vascular smooth muscle marker gene expression.

Pei-Yu Chen, Michael Simons, Robert Friesel

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. FGF/FGFR signaling in health and disease.Signal transduction and targeted therapy · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients.Clinical journal of the American Society of Nephrology : CJASN · 2018
    Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Pei-Yu ChenCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine 04074, USA. chenp@mmc.org
Michael Simons
Robert Friesel
Maine Medical Center Research Institute · USUniversity of Maine · USYale University · US

Funding

WNT SIGNALING IN PREIMPLANTATION EMBRYOP20RR018789 · NCRR · MAINE MEDICAL CENTER · PI WANG, ZACK Z. · 2003 to 2011
$18.9M
Angiogensis and ischemiaR01HL053793 · NHLBI · YALE UNIVERSITY · PI SIMONS, MICHAEL · 1996 to 2017
$7.3M
Feedback Inhibitory Mechanisms in Skeletal DevelopmentR01DK073871 · NIDDK · MAINEHEALTH · PI FRIESEL, ROBERT E · 2007 to 2011
$1.7M
DIAGNOSTIC LABORATORY FOR RESEARCH ANIMALSP40RR001555 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI SHALEV, MOSHE · 1985 to 1985
–
NCRR NIH HHS P20 RR1555NCRR NIH HHS P20RR18789NHLBI NIH HHS R01 HL053793NHLBI NIH HHS R01-HL53793NIDDK NIH HHS R01 DK073871NIDDK NIH HHS R01-DK073871
6 · The paper itself

Abstract

Vascular smooth muscle cells (VSMC) exhibit phenotypic plasticity and change from a quiescent contractile phenotype to a proliferative synthetic phenotype during physiological arteriogenesis and pathological conditions such as atherosclerosis and restenosis. Platelet-derived growth factor (PDGF)-BB is a potent inducer of the VSMC synthetic phenotype; however, much less is known about the role of fibroblast growth factor-2 (FGF2) in this process. Here, we show using signal transduction mutants of FGF receptor 1 (FGFR1) expressed in rat VSMC that the adaptor protein FRS2 is essential for FGFR1-mediated phenotypic modulation and down-regulation of VSMC smooth muscle alpha-actin (SMA) gene expression. In addition, we show that PDGF-BB and FGF2 act synergistically to induce cell proliferation and down-regulate SMA and SM22alpha in VSMC. Furthermore, we show that PDGF-BB induces tyrosine phosphorylation of FGFR1 and that this phosphorylation is mediated by PDGF receptor-beta (PDGFRbeta), but not c-Src. We demonstrate that FRS2 co-immunoprecipitates with PDGFRbeta in a complex that requires FGFR1 and that both the extracellular and the intracellular domains of FGFR1 are required for association with PDGFRbeta, whereas the cytoplasmic domain of FGFR1 is required for FRS2 association with the FGFR1-PDGFRbeta complex. Knockdown of FRS2 in VSMC by RNA interference inhibited PDGF-BB-mediated down-regulation of SMA and SM22alpha without affecting PDGF-BB mediated cell proliferation or ERK activation. Together, these data support the notion that PDGFRbeta down-regulates SMA and SM22alpha through formation of a complex that requires FGFR1 and FRS2 and prove novel insight into VSMC phenotypic plasticity.

Indexed as

Gene ExpressionAdaptor Proteins, Signal TransducingAmino Acid SubstitutionAnimalsAortaCattleCell DivisionCell LineDNA PrimersHomeostasisHumansImmunohistochemistryKidneyMembrane ProteinsMuscle, Smooth, VascularMutagenesis, Site-DirectedAdaptor Proteins, Signal TransducingDNA PrimersFGFR1 protein, humanFRS2 protein, humanMembrane ProteinsReceptor, Fibroblast Growth Factor, Type 1Receptor, Platelet-Derived Growth Factor beta

Identifiers

PMID19339244
PMCPMC2708892
OpenAlexW2042259396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.